AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 142 min read$VNDA

Vanda Pharmaceuticals (VNDA) Phase III Trial for VQW-765 Misses

Vanda Pharmaceuticals (VNDA) announced its Phase III trial for VQW-765 failed to meet primary endpoints in treating acute anxiety. The company's P/S ratio is 1.21, below its historical median, and its GF Score is 66. Insider sales totaled $2.8M over the past year, with no purchases. VNDA's market cap is $255M, and it remains unprofitable.

Original reporting
gurufocus.com
Published Oct 14, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VNDA
Bearish
high confidence
Mentioned
$VNDA
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$VNDABearishHigh
01

Why it matters

The negative result removes a near‑term catalyst, likely prompting sell‑offs and heightened scrutiny of the company's pipeline.

02

Market read

The news is material for VNDA and may influence sentiment across small‑cap biotech stocks.

03

What to watch

Potential for the company to pivot the asset to a different indication or partner with a larger pharma could mitigate downside.

Relevance 8/10Novelty 9/10Timing: today

Background

Vanda Pharmaceuticals (NASDAQ: VNDA) announced its Phase III trial failure for VQW-765, a CNS drug candidate targeting anxiety.

Company-level read

Ticker impact

$VNDABearishHigh confidence
Context

Phase III trial for VQW-765 failed to meet primary endpoint, marking a setback for Vanda Pharmaceuticals.

Expected impact

downward pressure as the market prices in the lack of efficacy data

Evidence & confidence

Clinical trial outcomes are material for biotech valuations; a missed primary endpoint removes a potential revenue catalyst.

Market effects

Sector

Biotech sector may see broader risk aversion toward CNS programs after the miss.

Regional

U.S. biotech stocks could experience modest pullback in early trading.

Global

Limited to investors focused on U.S. listed biotech firms.

Counterpoint

What could challenge this read

If the trial data were misinterpreted, the miss could be a temporary dip and present a buying opportunity at a discount.

Key entities

  • company
    Vanda Pharmaceuticals

    Biotech firm developing CNS therapeutics, ticker VNDA.

Read at source← All news

StoryVanda Pharmaceuticals Phase III trial of VQW‑765 fails to meet primary endpoint

Also covered by

1 outlet

Related articles

OCT 16
$VNDAHighAI 8/10

Vanda Pharmaceuticals’ VQW-765 misses primary endpoint

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after hours as its Phase III trial for VQW-765 failed to meet the primary endpoint in treating acute anxiety in adults with social anxiety disorder. The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 30 U.S. sites.

thepharmaletter.com1 min
OCT 15
$VNDAMedAI 8/10

Phase 3 Trial of VQW-765 for Social Anxiety Disorder Misses Endpoint

Vanda Pharmaceuticals' phase 3 trial for VQW-765, an investigational treatment for social anxiety disorder, missed its primary endpoint. The study showed no significant difference in distress levels between participants receiving VQW-765 and those receiving a placebo. The company is evaluating the data, and the clinical program is currently on hold.

empr.com4 min
OCT 15
$VNDAMed

Vanda freezes Novartis-originated social anxiety program after late-stage disappointment

Vanda Pharmaceuticals halted development of VQW-765, a social anxiety drug licensed from Novartis, after it failed to show significant benefit in a late-stage study. The Phase 3 trial, focused on female participants, showed no distress reduction versus placebo. Vanda will analyze the full dataset before deciding next steps. Oppenheimer analysts noted this was a clean miss but do not expect it to significantly impact their estimates for Vanda.

biospace.com5 min
OCT 15
$VNDAHighAI 8/10

Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phas

Vanda Pharmaceuticals (VNDA) shares fell 2% premarket after its Phase III trial for anxiety drug VQW-765 failed to meet primary and key secondary endpoints. The company paused the program for further analysis, confirming the drug's safety. VNDA's P/S ratio is 1.16, below historical and industry medians, reflecting market skepticism. Insider selling totaled $2.8M, with mixed institutional sentiment.

gurufocus.com2 min
OCT 14
$VNDAHighAI 8/10

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.

investing.com2 min
OCT 14
$VNDAMedAI 8/10

Vanda’s phase III trial for social anxiety drug fails

Vanda Pharmaceuticals (VNDA) reported that its phase III trial for VQW-765, a drug for social anxiety, failed to meet primary and secondary endpoints. The study showed no significant difference in distress levels between the drug and placebo. The company has paused the program pending further analysis. The drug was safe and well-tolerated, according to the company.

investing.com2 min